Samyang Biopharm Holds 1st Regular Shareholders' Meeting
From November 1 Spin-Off to Year-End
Sales of 28.6 Billion Won and Operating Profit of 2.7 Billion Won
Samyang Biopharm announced that it held its 1st regular shareholders' meeting on March 23 at Samyang Hall on the basement 1st floor of the Samyang Discovery Center in Pangyo, Seongnam, Gyeonggi Province.
At the shareholders' meeting, all four agenda items were approved as originally proposed: approval of the 1st term financial statements, partial amendment of the articles of incorporation, appointment of an outside director as an audit committee member, and approval of the directors' remuneration limit.
Samyang Biopharm held its first regular shareholders' meeting on the 23rd at Samyang Hall, Basement 1, Samyang Discovery Center in Pangyo. Samyang Biopharm
View original imageSamyang Biopharm reported sales of 28.6 billion won and operating profit of 2.7 billion won for the period from the date of the spin-off, November 1 last year, to the end of the year.
In his welcoming remarks, CEO Kim Kyungjin said, "Samyang Biopharm has enhanced its portfolio by focusing on medical devices, pharmaceuticals, and new drug development, and has improved profitability through proactive global market expansion. This year, with an even bolder spirit of challenge, we will continue to create opportunities for sustainable growth and innovation."
He further stated, "We aim to become a healthcare solution partner that enhances the quality of human life by diversifying our medical device business portfolio, accelerating our entry into the aesthetic medical field, advancing and developing new technologies for our gene therapy drug delivery platform 'SENS,' driving new drug development, expanding anticancer drug sales, and broadening our mid- to long-term pharmaceutical portfolio."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Samyang Biopharm has been operating under the leadership of CEO Kim Kyungjin since it was spun off from Samyang Holdings, the holding company of Samyang Group, on November 1 last year.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.